Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

TAK-186 · MVC-101

Bispecific antibody · Immune activation, directed at EGFR and CD3 (CD3E) · developed by TAKEDA PHARMACEUTICAL CO

Phase 1/2 Most advanced trial (none active)

TAK Developer

1 Registered trials

What is TAK-186?

TAK-186 is a T-cell engaging bispecific antibody with a protease-cleavable linker and albumin-binding domain. It binds EGFR on tumor cells and CD3 on cytotoxic T-lymphocytes, redirecting T-cells to kill EGFR-expressing tumors. It is studied in head and neck squamous cell carcinoma, non-small cell lung cancer, and colorectal cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: MVC-101
Drug type: Bispecific antibody
Targets: EGFR, CD3 (CD3E), human serum albumin (ALB) (binding partner it blocks)
Mechanism: Immune activation, directed at EGFR and CD3 (CD3E)
Pathways: T-cell activation, tumor cell killing
Therapy area: Oncology
Developer: TAKEDA PHARMACEUTICAL CO (TAK)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII: SZ7226875S

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT04844073	Phase 1/2	Squamous Cell Cancer of Head and Neck (SCCHN)	Terminated	TAK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Colorectal CancerNon-small Cell Lung Cancer (NSCLC)Squamous Cell Cancer of Head and Neck (SCCHN)

Other drugs acting on EGFR / CD3E

Anti-Thymocyte Globulin FDA approved Blinatumomab FDA approved Neratinib FDA approved Osimertinib FDA approved Actinium Ac 225 FPI-2068 Phase 1 ALX2004 Phase 1 AZD5492 Phase 1/2 BH-30643 Phase 1/2 CT-95 Phase 1 CUDC-101 Phase 1 EGFR-TKI inhibitor based on investigator's choice Phase 3 Enozertinib Phase 1/2

More from TAKEDA PHARMACEUTICAL CO

Maribavir FDA approved Susoctocog Alfa FDA approved Vedolizumab FDA approved Vonicog Alfa FDA approved Elritercept Phase 3 GDX012 Phase 1/2 IGI Phase 3 Mezagitamab Phase 3 MNI-792 Phase 1 Pevonedistat Phase 2/3 Soticlestat Phase 3 TAK-188 Phase 1/2

Sources

NCI Thesaurus

Updated Oct 3, 2026. Something wrong or missing? Report it on the TAK page.

Follow TAK, the company behind TAK-186

See TAK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TAK catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z